

# T Jake Liang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10702994/publications.pdf>

Version: 2024-02-01

137  
papers

20,045  
citations

11608

70  
h-index

11288

136  
g-index

141  
all docs

141  
docs citations

141  
times ranked

18492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells. <i>Hepatology</i> , 2021, 74, 2998-3017.	3.6	35
2	Controlled Human Infection Model – Fast Track to HCV Vaccine?. <i>New England Journal of Medicine</i> , 2021, 385, 1235-1240.	13.9	22
3	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. <i>Cell Chemical Biology</i> , 2020, 27, 780-792.e5.	2.5	18
4	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , 2020, 130, 3205-3220.	3.9	38
5	Hepatitis C Virus Infection Induces Hepatic Expression of NF- $\kappa$ B-Inducing Kinase and Lipogenesis by Downregulating miR-122. <i>MBio</i> , 2019, 10, .	1.8	12
6	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2019, 163, 149-155.	1.9	6
7	Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. <i>Antiviral Therapy</i> , 2019, 24, 371-381.	0.6	5
8	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
9	Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2019, 156, 311-324.	0.6	85
10	17 $\beta$ -Hydroxysteroid Dehydrogenase 13 is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1504-1519.	3.6	200
11	MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. <i>Virologica Sinica</i> , 2019, 34, 197-210.	1.2	19
12	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1761-1769.	1.9	11
13	N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
14	TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. <i>Gastroenterology</i> , 2018, 155, 1923-1935.e8.	0.6	11
15	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN $\gamma$ . <i>Gut</i> , 2017, 66, 724-735.	6.1	55
16	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. <i>Gastroenterology</i> , 2017, 152, 1297-1309.	0.6	442
17	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6364-6383.	2.9	12
18	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. <i>Nature Communications</i> , 2017, 8, 1789.	5.8	70

#	ARTICLE	IF	CITATIONS
19	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. <i>Gastroenterology</i> , 2017, 152, 257-270.e7.	0.6	43
20	Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. <i>Journal of Hepatology</i> , 2017, 66, 494-503.	1.8	105
21	Evaluation of antiviral drug synergy in an infectious HCV system. <i>Antiviral Therapy</i> , 2016, 21, 595-603.	0.6	18
22	Experimental models of hepatitis B and C – new insights and progress. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 362-374.	8.2	70
23	Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. <i>Stem Cell Research</i> , 2016, 16, 640-650.	0.3	74
24	Hepatitis C Virus: From Obscurity to the Lasker. <i>Gastroenterology</i> , 2016, 151, 1052-1053.	0.6	1
25	Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7620-7625.	3.3	50
26	The X-Files of hepatitis B. <i>Nature</i> , 2016, 531, 313-314.	13.7	6
27	Hepatitis B Virus – Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
28	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 841-853.	2.9	30
29	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	3.6	269
30	Dynamic Interaction of Stress Granules, DDX3X, and IKK- $\beta$ Mediates Multiple Functions in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5462-5477.	1.5	67
31	Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. <i>ACS Infectious Diseases</i> , 2015, 1, 416-419.	1.8	2
32	Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection. <i>Journal of Innate Immunity</i> , 2015, 7, 530-544.	1.8	31
33	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. <i>Gastroenterology</i> , 2015, 149, 190-200.e2.	0.6	222
34	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. <i>Science Translational Medicine</i> , 2015, 7, 282ra49.	5.8	118
35	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. <i>Antiviral Research</i> , 2015, 124, 20-29.	1.9	9
36	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. <i>ACS Combinatorial Science</i> , 2015, 17, 641-652.	3.8	23

#	ARTICLE	IF	CITATIONS
37	Single Strain Isolation Method for Cell Culture-Adapted Hepatitis C Virus by End-Point Dilution and Infection. PLoS ONE, 2014, 9, e98168.	1.1	7
38	Integrative Functional Genomics of Hepatitis C Virus Infection Identifies Host Dependencies in Complete Viral Replication Cycle. PLoS Pathogens, 2014, 10, e1004163.	2.1	101
39	What is the future of ribavirin therapy for hepatitis C?. Antiviral Research, 2014, 104, 34-39.	1.9	41
40	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	6.0	774
41	Ribavirin improves the IFN- $\lambda$ 3 response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology, 2014, 60, 1160-1169.	3.6	26
42	Therapy of Hepatitis C “Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047.	13.9	102
43	Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF- $\kappa$ B and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. Journal of Virology, 2014, 88, 1582-1590.	1.5	96
44	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	1.4	30
45	Alternative interferons and immunomodulators in the treatment of hepatitis C. Liver International, 2014, 34, 133-138.	1.9	3
46	Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. Journal of Clinical Investigation, 2014, 124, 4953-4964.	3.9	131
47	Impact of host and virus genome variability on HCV replication and response to interferon. Current Opinion in Virology, 2013, 3, 501-507.	2.6	5
48	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology, 2013, 58, 1548-1557.	3.6	96
49	Hepatitis C virus infection activates an innate pathway involving IKK- $\zeta$ in lipogenesis and viral assembly. Nature Medicine, 2013, 19, 722-729.	15.2	167
50	Current progress in development of hepatitis C virus vaccines. Nature Medicine, 2013, 19, 869-878.	15.2	144
51	Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine, 2013, 368, 1907-1917.	13.9	418
52	Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine, 2013, 369, 679-680.	13.9	45
53	Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 2012, 156, 743.	2.0	74
54	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy, 2012, 23, 1-12.	0.3	109

#	ARTICLE	IF	CITATIONS
55	Cryo-EM study of Hepatitis B virus core antigen capsids decorated with antibodies from a human patient. <i>Journal of Structural Biology</i> , 2012, 177, 145-151.	1.3	11
56	HCV Infection Induces a Unique Hepatic Innate Immune Response Associated With Robust Production of Type III Interferons. <i>Gastroenterology</i> , 2012, 142, 978-988.	0.6	241
57	Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses. <i>Gastroenterology</i> , 2011, 140, 676-685.e1.	0.6	52
58	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. <i>Nature Genetics</i> , 2011, 43, 1131-1138.	9.4	501
59	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , 2011, 53, 32-41.	3.6	140
60	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. <i>Hepatology</i> , 2011, 54, 425-433.	3.6	21
61	Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 47-59.	3.6	153
62	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 894-903.	3.6	403
63	Novel Function of CD81 in Controlling Hepatitis C Virus Replication. <i>Journal of Virology</i> , 2010, 84, 3396-3407.	1.5	35
64	Inhibition of Cellular Proteasome Activities Mediates HBX-Independent Hepatitis B Virus Replication <i>In Vivo</i> . <i>Journal of Virology</i> , 2010, 84, 9326-9331.	1.5	20
65	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alpha-Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2.	0.6	243
66	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16410-16415.	3.3	333
67	Hepatitis B: The virus and disease. <i>Hepatology</i> , 2009, 49, S13-S21.	3.6	739
68	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry. <i>Gastroenterology</i> , 2009, 137, 673-681.	0.6	78
69	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1130-1137.	2.4	62
70	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. <i>Hepatology</i> , 2008, 48, 732-740.	3.6	56
71	Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. <i>Journal of Virology</i> , 2008, 82, 3466-3479.	1.5	79
72	Mouse models for the study of HCV infection and virus-host interactions. <i>Journal of Hepatology</i> , 2008, 49, 134-142.	1.8	51

#	ARTICLE	IF	CITATIONS
73	Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. <i>Gastroenterology</i> , 2008, 134, 405-415.	0.6	215
74	Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1243-1248.	2.4	40
75	Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B-Related Outcomes After Liver Transplantation: Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 696-700.	2.4	105
76	Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy. <i>Annals of Internal Medicine</i> , 2008, 148, 519.	2.0	407
77	Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance. <i>PLoS ONE</i> , 2008, 3, e3442.	1.1	22
78	Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8427-8432.	3.3	157
79	A functional SNP of interferon- $\lambda$ 3 gene is important for interferon- $\lambda$ 3-induced and spontaneous recovery from hepatitis C virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 985-990.	3.3	109
80	Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 "Is Less More?". <i>New England Journal of Medicine</i> , 2007, 357, 176-178.	13.9	8
81	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. <i>Journal of Virology</i> , 2007, 81, 4405-4411.	1.5	95
82	Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 733-744.	0.6	100
83	Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy. <i>Gastroenterology</i> , 2007, 132, 1757-1766.	0.6	105
84	Management of hepatitis B: Summary of a clinical research workshop. <i>Hepatology</i> , 2007, 45, 1056-1075.	3.6	568
85	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2007, 46, 424-429.	3.6	227
86	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , 2007, 46, 1548-1563.	3.6	242
87	Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. <i>Virology</i> , 2007, 367, 126-134.	1.1	51
88	Treatment of chronic hepatitis B. <i>Antiviral Therapy</i> , 2007, 12 Suppl 3, H33-41.	0.6	7
89	Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1048-1052.	2.4	90
90	Src Homology 3 Domain of Hepatitis C Virus NS5A Protein Interacts With Bin1 and Is Important for Apoptosis and Infectivity. <i>Gastroenterology</i> , 2006, 130, 794-809.	0.6	62

#	ARTICLE	IF	CITATIONS
91	Natural history of hbeag-negative chronic Hepatitis b. <i>Current Hepatitis Reports</i> , 2006, 5, 27-32.	0.3	0
92	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. <i>Hepatology</i> , 2006, 43, 780-787.	3.6	70
93	Hepatitis C virus entry: Molecular biology and clinical implications. <i>Hepatology</i> , 2006, 44, 527-535.	3.6	116
94	Altered Proteolysis and Global Gene Expression in Hepatitis B Virus X Transgenic Mouse Liver. <i>Journal of Virology</i> , 2006, 80, 1405-1413.	1.5	35
95	Novel approaches to new therapies for hepatitis B virus infection. <i>Antiviral Therapy</i> , 2006, 11, 1-15.	0.6	10
96	Novel Approaches to New Therapies for Hepatitis B Virus Infection. <i>Antiviral Therapy</i> , 2006, 11, 1-15.	0.6	23
97	Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. <i>Blood</i> , 2005, 105, 3605-3614.	0.6	86
98	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. <i>Nature Medicine</i> , 2005, 11, 791-796.	15.2	2,561
99	Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primaryTupaiahepatocytes. <i>Hepatology</i> , 2005, 41, 247-256.	3.6	55
100	Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. <i>Journal of General Virology</i> , 2005, 86, 3291-3301.	1.3	37
101	An in vitro model of hepatitis C virion production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2579-2583.	3.3	104
102	Robust Production of Infectious Hepatitis C Virus (HCV) from Stably HCV cDNA-Transfected Human Hepatoma Cells. <i>Journal of Virology</i> , 2005, 79, 13963-13973.	1.5	144
103	Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity. <i>Journal of Virology</i> , 2004, 78, 7257-7263.	1.5	98
104	Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. <i>Journal of Virology</i> , 2004, 78, 9030-9040.	1.5	70
105	Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2004, 78, 6995-7003.	1.5	106
106	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2004, 39, 188-196.	3.6	679
107	Effects of antiviral therapy on the cellular immune response in acute hepatitis C. <i>Hepatology</i> , 2004, 40, 87-97.	3.6	130
108	Pathogenesis of hepatitis C-associated hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S62-S71.	0.6	203

#	ARTICLE	IF	CITATIONS
109	Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. <i>Biochemical Journal</i> , 2004, 379, 199-208.	1.7	29
110	Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. <i>Hepatology</i> , 2003, 37, 52-59.	3.6	48
111	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. <i>Hepatology</i> , 2003, 38, 66-74.	3.6	83
112	Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1075-1086.	3.6	340
113	Progression of fibrosis in chronic hepatitis C. <i>Gastroenterology</i> , 2003, 124, 97-104.	0.6	368
114	Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6753-6758.	3.3	152
115	The Clearance of Hepatitis C Virus Infection in Chimpanzees May Not Necessarily Correlate with the Appearance of Acquired Immunity. <i>Journal of Virology</i> , 2003, 77, 862-870.	1.5	84
116	Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2002, 169, 3447-3458.	0.4	596
117	Hepatitis B e Antigen – The Dangerous Endgame of Hepatitis B. <i>New England Journal of Medicine</i> , 2002, 347, 208-210.	13.9	31
118	Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry. <i>Journal of Virology</i> , 2002, 76, 9335-9344.	1.5	113
119	Structural Features of Envelope Proteins on Hepatitis C Virus-like Particles as Determined by Anti-envelope Monoclonal Antibodies and CD81 Binding. <i>Virology</i> , 2002, 298, 124-132.	1.1	71
120	Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. <i>Hepatology</i> , 2001, 34, 417-423.	3.6	90
121	Monoclonal Antibodies with Broad Specificity for Hepatitis C Virus Hypervariable Region 1 Variants Can Recognize Viral Particles. <i>Journal of Immunology</i> , 2001, 167, 3878-3886.	0.4	29
122	X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. <i>Journal of Clinical Investigation</i> , 2001, 108, 1523-1531.	3.9	57
123	Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. <i>Annals of Internal Medicine</i> , 2000, 132, 296.	2.0	764
124	Long-Term Therapy of Chronic Hepatitis B With Lamivudine. <i>Hepatology</i> , 2000, 32, 828-834.	3.6	326
125	Antibodies Against Hepatitis C Virus-Like Particles and Viral Clearance in Acute and Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 610-617.	3.6	72
126	Vaccine Development for Hepatitis C. <i>Seminars in Liver Disease</i> , 2000, 20, 211-226.	1.8	67



#	ARTICLE	IF	CITATIONS
127	I Molecular biology of hepatitis C virus. Biomedical Research Reports, 2000, 2, 1-1.	0.3	6
128	Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells. Journal of Virology, 1998, 72, 3827-3836.	1.5	345
129	Naturally Occurring Mutations Define a Novel Function of the Hepatitis B Virus Core Promoter in Core Protein Expression. Journal of Virology, 1998, 72, 6785-6795.	1.5	75
130	Acute and Chronic Hepatitis B and D. , 1998, , 121-129.		0
131	Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. Journal of Medical Virology, 1994, 42, 151-157.	2.5	36
132	Vaccination against hepatitis C virus infection: Miles to go before we sleep. Hepatology, 1994, 20, 758-760.	3.6	7
133	HCV RNA in patients with chronic hepatitis C treated with interferon- $\alpha$ . Journal of Medical Virology, 1993, 40, 69-75.	2.5	8
134	A Hepatitis B Virus Mutant Associated with an Epidemic of Fulminant Hepatitis. New England Journal of Medicine, 1991, 324, 1705-1709.	13.9	474
135	Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology, 1991, 13, 1044-1051.	3.6	88
136	Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. Hepatology, 1991, 14, 56-63.	3.6	106
137	Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology, 1990, 12, 204-212.	3.6	115